In vitro and in vivo efficacy of a novel fluoro-ketolide HMR 3562 against enterococci.
The in vitro activity of HMR 3562, a new 2-fluoro-ketolide drug, was investigated against 95 enterococci, including 36 vancomycin-resistant strains. HMR 3562 inhibited 90% of enterococci susceptible or resistant to erythromycin A at 0.005 and 0.6 mg/L, respectively. HMR 3562 was highly active in murine peritonitis induced by five enterococci, irrespective of resistance phenotype, displaying effective doses in the range 3.4-21.8 mg/kg. The results demonstrate the potential of HMR 3562 in the treatment of infections caused by multiresistant enterococci.
Guitton
M
M
Aventis Pharma, Infectious Diseases Group, Microbiology, 102, Route de Noisy, 93235 Romainville Cedex, France.
Delachaume
C
C
Le Priol
P
P
Steier
V
V
Bonnefoy
A
A
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016983:Enterococcus / Q000187:drug effects*; D018942:Macrolides; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D008826:Microbial Sensitivity Tests; D010538:Peritonitis / Q000188:drug therapy; D020713:Vancomycin Resistance
D000900:Anti-Bacterial Agents; C438106:HMR 3562; D018942:Macrolides